Preclinical studies using transgenic AD mouse models and in vitro systems have demonstrated that MSCs derived from bone marrow and other tissues enhance amyloid-β (Aβ) clearance and attenuate tau hyperphosphorylation [12]. This evidence concerns the gene MAPT and Alzheimer disease.